Skip to main content

Security report for gileadclinicaltrials.com

Gilead Sciences, Inc · Healthcare · United States

Medium risk. 5 critical or high findings in Security headers and GDPR outside view.

Security score

70/100

Risk levelMedium

0–100, higher is better. How it is calculated

Gilead Clinical Trials website serves as an educational and informational platform dedicated to providing patients in the United States with comprehensive resources about clinical trials in areas such as breast cancer, HIV prevention, and other therapeutic indications. The site reflects Gilead Sciences, Inc's commitment to transparency and patient engagement in clinical research, supporting their broader mission to develop transformative medicines. The website is professionally designed, mobile-optimized, and integrates modern web technologies to deliver a seamless user experience. From a technical perspective, the site leverages a robust technology stack including jQuery, Bootstrap, Mapbox for geolocation services, and Owl Carousel for interactive content presentation. The use of Google Tag Manager indicates a mature approach to analytics and marketing. The website demonstrates good SEO and accessibility practices, ensuring broad reach and usability. Security-wise, the site uses HTTPS and includes CSRF protection tokens in forms, but lacks explicit security headers and a public incident response or vulnerability disclosure policy. The absence of WHOIS domain registration data is a notable concern, potentially indicating privacy protection or registry issues, which slightly impacts the trustworthiness score. However, the strong branding, official links, and comprehensive privacy and legal policies mitigate this concern. Overall, the website presents a high level of professionalism, content quality, and user trustworthiness, with recommendations to enhance security headers and publish incident response information to further strengthen its security posture.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

Need hands-on remediation? Email guard@offseq.com

Keep watching gileadclinicaltrials.com

This scan found 21 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
95
Security headers
20
Email security
70
DNS health
80
Network security
100
GDPR outside view
53
Average
70

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Gilead Sciences is a leading pharmaceutical company with a strong market position in healthcare, particularly in antiviral therapies and oncology. This clinical trials site supports their business model by providing transparency and patient education, which are critical for recruitment and retention in clinical research. The site targets patients and healthcare providers in the United States, emphasizing inclusivity and diversity in clinical trials. The integration with the main corporate site and social media channels indicates a well-established partnership ecosystem. The business benefits from a large enterprise scale, leveraging digital tools to enhance patient engagement and regulatory compliance. Growth indicators include active featured trials and educational content, positioning Gilead as a trusted innovator in clinical research.

Security posture

The website demonstrates a moderate to good security maturity level. HTTPS is enforced, and forms include anti-CSRF tokens, which protect against common web vulnerabilities. However, the lack of visible security headers such as Content Security Policy (CSP), HTTP Strict Transport Security (HSTS), and X-Frame-Options reduces the overall security posture. No public incident response or vulnerability disclosure mechanisms are present, which limits transparency in security management. Data protection practices appear compliant with privacy laws, supported by comprehensive privacy and cookie policies. The site does not expose sensitive data or use vulnerable libraries based on the provided content. Enhancing security headers and publishing a security policy would improve readiness and trust.

Recommendations

  1. Implement and enforce security headers including CSP, HSTS, X-Frame-Options, and X-XSS-Protection to mitigate common web attacks.
  2. Publish an incident response and vulnerability disclosure policy or security.txt file to improve transparency and user trust.
  3. Verify and update WHOIS domain registration information to ensure domain legitimacy and reduce suspicion.
  4. Conduct regular security audits and update third-party libraries to avoid vulnerabilities.
  5. Enhance user privacy controls and clearly communicate data retention policies to align with GDPR and other regulations.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Gilead Sciences, Inc
Description
Gilead Clinical Trials website provides educational and informational content about clinical trials related to breast cancer, HIV prevention, and other therapeutic areas. It supports Gilead's vision of advancing transformative medicines and therapies.
Key services
Clinical trial information and search, Patient education on clinical trials, Transparency policy communication
Content quality
excellent
Branding
consistent

Technology

Stack
jQuery 3.7.1, Bootstrap 4.5.3, Font Awesome 6.2.1, Mapbox GL JS, Mapbox GL Geocoder, Owl Carousel 2.3.4, jQuery UI 1.13.1
Frameworks
Bootstrap
Performance
moderate
Mobile
excellent
Accessibility
good
SEO
good

Security

Observed score
75/100
Good practices seen
  • Use of HTTPS (implied by canonical URL and external links)
  • No exposed sensitive data in HTML
  • Use of token for CSRF protection in form

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and interactive features
  2. Strong focus on patient education and clinical trial transparency
  3. No signs of malicious or suspicious content
  4. Good use of modern web technologies and responsive design
  5. WHOIS data missing, which is unusual and warrants further investigation
Technical notes

Notes

The website is built on a modern and stable technology stack featuring jQuery, Bootstrap, Mapbox, and Owl Carousel, which supports responsive design and interactive features. The use of Google Tag Manager facilitates advanced analytics and marketing capabilities. Performance is moderate, with potential improvements in loading speed by optimizing assets and scripts. Accessibility is good, with semantic HTML and ARIA roles likely implemented. No CMS is explicitly detected, suggesting a custom or proprietary platform. Hosting details are not disclosed, but the site uses HTTPS and external CDN resources. Technical debt appears low, though adding security headers and improving domain registration transparency would reduce risks.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with gileadclinicaltrials.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review gileadclinicaltrials.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.